Advertisement

Surgeon-Led Clinical Trials in Pancreatic Cancer

  • Akhil Chawla
    Affiliations
    Division of Surgical Oncology, Department of Surgery, Northwestern Medicine Regional Medical Group, Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 650Chicago, IL 60611, USA

    Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Search for articles by this author
  • Cristina R. Ferrone
    Correspondence
    Corresponding author. Wang 460, 15 Parkman Street, Boston, MA 02114.
    Affiliations
    Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
    Search for articles by this author
Published:November 03, 2022DOI:https://doi.org/10.1016/j.soc.2022.08.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 2013; 369: 1691-1703https://doi.org/10.1056/NEJMoa1304369
        • Conroy T.
        • Paillot B.
        • François E.
        • et al.
        Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
        J Clin Oncol. 2005; 23: 1228-1236https://doi.org/10.1200/JCO.2005.06.050
        • Oettle H.
        • Neuhaus P.
        • Hochhaus A.
        • et al.
        Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
        JAMA. 2013; 310: 1473-1481https://doi.org/10.1001/jama.2013.279201
        • Neoptolemos J.P.
        • Stocken D.D.
        • Friess H.
        • et al.
        A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med.
        . 2004; 350: 1200-1210https://doi.org/10.1056/NEJMoa032295
        • Maeda A.
        • Boku N.
        • Fukutomi A.
        • et al.
        Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
        Jpn J Clin Oncol. 2008; 38: 227-229https://doi.org/10.1093/jjco/hym178
        • Neoptolemos J.P.
        • Palmer D.H.
        • Ghaneh P.
        • et al.
        Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
        Lancet. 2017; 389: 1011-1024https://doi.org/10.1016/s0140-6736(16)32409-6
        • Murphy J.E.
        • Wo J.Y.
        • Ryan D.P.
        • et al.
        Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
        JAMA Oncol. 2018; https://doi.org/10.1001/jamaoncol.2018.0329
        • Murphy J.E.
        • Wo J.Y.
        • Ryan D.P.
        • et al.
        Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
        JAMA Oncol. 2019; https://doi.org/10.1001/jamaoncol.2019.0892
        • Katz M.H.
        • Shi Q.
        • Ahmad S.A.
        • et al.
        Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
        JAMA Surg. 2016; 151: e161137https://doi.org/10.1001/jamasurg.2016.1137
        • Jang J.Y.
        • Han Y.
        • Lee H.
        • et al.
        Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
        Ann Surg. 2018; 268: 215-222https://doi.org/10.1097/sla.0000000000002705
        • Tempero M.A.
        • Reni M.
        • Riess H.
        • et al.
        APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
        J Clin Oncol. 2019; 37: 4000https://doi.org/10.1200/JCO.2019.37.15_suppl.4000
        • Tempero M.
        • O'Reilly E.
        • Van Cutsem E.
        • et al.
        LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival.
        Ann Oncol. 2021; 32: S226https://doi.org/10.1016/j.annonc.2021.06.009
        • Conroy T.
        • Hammel P.
        • Hebbar M.
        • et al.
        FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
        N Engl J Med. 2018; 379: 2395-2406https://doi.org/10.1056/NEJMoa1809775
        • Conroy T.
        • Hammel P.
        • Turpin A.
        • et al.
        LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC).
        Ann Oncol. 2021; 32: S1334https://doi.org/10.1016/j.annonc.2021.08.2137
        • Hsu C.C.
        • Herman J.M.
        • Corsini M.M.
        • et al.
        Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
        Ann Surg Oncol. 2010; 17: 981-990https://doi.org/10.1245/s10434-009-0743-7
        • Sohal D.
        • Duong M.T.
        • Ahmad S.A.
        • et al.
        SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).
        J Clin Oncol. 2020; 38: 4504https://doi.org/10.1200/JCO.2020.38.15_suppl.4504
        • Chawla A.
        • Ferrone C.R.
        Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift.
        Front Oncol. 2019; 9: 1085https://doi.org/10.3389/fonc.2019.01085
        • Unno M.
        • Motoi F.
        • Matsuyama Y.
        • et al.
        Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
        J Clin Oncol. 2019; 37: 189https://doi.org/10.1200/JCO.2019.37.4_suppl.189
        • de Bono J.S.
        • Twelves C.J.
        The oral fluorinated pyrimidines.
        Invest New Drugs. 2001; 19: 41-59https://doi.org/10.1023/a:1006404701008
        • Satoi S.
        • Unno M.
        • Motoi F.
        • et al.
        The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).
        J Clin Oncol. 2019; 37: 4126https://doi.org/10.1200/JCO.2019.37.15_suppl.4126
        • Katz M.H.
        • Marsh R.
        • Herman J.M.
        • et al.
        Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
        Ann Surg Oncol. 2013; 20: 2787-2795https://doi.org/10.1245/s10434-013-2886-9
      1. NCCN. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma Version 1.2022. National Comprehensive Cancer Network.
        (Available at:) (Accessed 05/01/2022)
        • Ahmad S.A.
        • Duong M.
        • Sohal D.P.S.
        • et al.
        Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
        Ann Surg. 2020; https://doi.org/10.1097/SLA.0000000000004155
        • de W Marsh R.
        • Talamonti M.S.
        • Baker M.S.
        • et al.
        Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.
        J Surg Oncol. 2018; 117: 354-362https://doi.org/10.1002/jso.24872
        • Versteijne E.
        • Suker M.
        • Groothuis K.
        • et al.
        Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
        J Clin Oncol. 2020; 38: 1763-1773https://doi.org/10.1200/jco.19.02274
        • Kunzmann V.
        • Siveke J.T.
        • Algül H.
        • et al.
        Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
        Lancet Gastroenterol Hepatol. 2021; 6: 128-138https://doi.org/10.1016/S2468-1253(20)30330-7
        • Chawla A.
        • Qadan M.
        • Castillo C.F.
        • et al.
        Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma.
        Ann Surg. 2020; https://doi.org/10.1097/SLA.0000000000004585